KMTS (Kestra Medical Technologies) NonCurrent Deferred Revenue: $0.00 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
12 GF Score
Price $25.63
! 6 Warning Signs
View Full Analysis

What is Kestra Medical Technologies NonCurrent Deferred Revenue?

Kestra Medical Technologies KMTS -0.70% 12 NonCurrent Deferred Revenue is $0.00 Mil as of Apr. 2026. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Kestra Medical Technologies's non-current deferred revenue for the quarter that ended in Apr. 2026 was $0.00 Mil.

Kestra Medical Technologies NonCurrent Deferred Revenue Related Terms

Kestra Medical Technologies NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies NonCurrent Deferred Revenue Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24 Apr25 Apr26
NonCurrent Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KMTS
12GF Score
Kestra Medical Technologies Ltd KMTS
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Kestra Medical Technologies (KMTS) has a NonCurrent Deferred Revenue of $0.00 Mil as of Apr. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' NonCurrent Deferred Revenue too high?
Kestra Medical Technologies' current NonCurrent Deferred Revenue is $0.00 Mil. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' NonCurrent Deferred Revenue compare to AZTA and STAA?
Kestra Medical Technologies' NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Devices & Instruments company?
A good NonCurrent Deferred Revenue depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Kestra Medical Technologies and its competitors. Kestra Medical Technologies's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current NonCurrent Deferred Revenue of $0.00 Mil. The current NonCurrent Deferred Revenue is $0.00 Mil. Kestra Medical Technologies' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current NonCurrent Deferred Revenue is $0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score

Get the complete analysis for KMTS

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.63
Price